改性壳聚糖基纳米核酸药物的制备及性能研究  

Preparation and Properties of Nano-nucleic Acid Drug Based on Modified Chitosan

作　　者：林冠权 LIN Guan-quan(Sirnaomics Biopharmaceuticals(Guangzhou)Co.,Ltd.,Guangdong Guangzhou 51000,China)

机构地区：[1]圣诺生物医药技术(广州)有限公司,广东广州510000

出　　处：《广州化工》2022年第21期102-104,共3页GuangZhou Chemical Industry

摘　　要：通过接枝聚合制备壳聚糖-聚二甲基二烯丙基氯化铵(CP)核酸载体,采用核磁共振氢谱对CP的结构进行表征;CP、离子交联剂三聚磷酸钠(ST)与小干扰核酸(siRNA)通过静电作用力自组装形成纳米核酸药物,并研究其细胞活性及抑制目的基因表达性能。结果显示,CP不具备细胞毒性且在CP:ST:siRNA的质量比为24:2:1时,纳米核酸药物对胰腺癌(BXPC3)细胞的活性具有一定的抑制作用。此外,纳米核酸药物对目的基因的表达具有良好的抑制作用。Chitosan-polydiallyldimethylammonium chloride(CS-G-PDMDAAC)nucleic acid carrier was prepared by graft polymerization,and the structure was characterized by 1H NMR.CS-g-PDMDAAC,sodium triphosphate acid(ST)and small interfering RNA(siRNA)were self-assembled by electrostatic force to form nano-nucleic acid drug.The cell activity and the ability of inhibiting target gene expression of nano-nucleic acid drug were studied.The results showed that CS-g-PDMDAAC had no cytotoxicity,and the nano-nucleic acid drug had inhibitory effect on the activity of pancreatic cancer cells(BXPC3)when the mass ratio of CS-g-PDMDAAC:ST:siRNA was 24:2:1.In addition,the nano-nucleic acid drug had a good inhibitory effect on the expression of the target gene.

关 键 词：壳聚糖 二甲基二烯丙基氯化铵 小干扰核酸 纳米核酸药物 

分 类 号：O69[理学—化学]